Jounce Therapeutics, Inc. (JNCE)
| Market Cap | 464.90M |
| Revenue (ttm) | 62.34M |
| Net Income (ttm) | -43.84M |
| Shares Out | 35.43M |
| EPS (ttm) | -1.24 |
| PE Ratio | n/a |
| Forward PE | 21.14 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | April 19 |
| Last Price | $8.57 |
| Previous Close | $9.09 |
| Change ($) | -0.52 |
| Change (%) | -5.72% |
| Day's Open | 8.97 |
| Day's Range | 8.52 - 9.26 |
| Day's Volume | 76,309 |
| 52-Week Range | 4.30 - 14.84 |
CAMBRIDGE, Mass., April 12, 2021 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predi...
-Translational analysis of patients that do not respond to PD-(L)1 inhibitors show high pretreatment intratumoral LILRB2 expression relative to an IFNγ gene signature-
CAMBRIDGE, Mass., March 12, 2021 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (Nasdaq: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predi...
CAMBRIDGE, Mass., March 10, 2021 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predi...
CAMBRIDGE, Mass., March 09, 2021 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (Nasdaq: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predi...
CAMBRIDGE, Mass., March 09, 2021 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (Nasdaq: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predi...
- Commenced enrollment in both the Phase 1 INNATE trial of JTX-8064 (LILRB2 / ILT4) and the Phase 2 SELECT trial of Vopratelimab in combination with JTX-4014 -
CAMBRIDGE, Mass., Feb. 23, 2021 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predic...
CAMBRIDGE, Mass., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predic...
CAMBRIDGE, Mass., Feb. 12, 2021 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predic...
Time will always be on the investor's side.
These baby biotechs are itching to come out of their shells.
CAMBRIDGE, Mass., Jan. 08, 2021 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predic...
Jounce is developing several novel immunotherapies that target T cells and macrophages. I am bearish on the success of Vopratelimab and JTX-8064 and neutral on the prospects of JTX-4014 and JTX-1811.
Investors need to pay close attention to Jounce Therapeutics (JNCE) stock based on the movements in the options market lately.
CAMBRIDGE, Mass., Dec. 16, 2020 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predic...
CAMBRIDGE, Mass., Nov. 25, 2020 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predic...
-Phase 1 INNATE trial will evaluate JTX-8064 as a monotherapy and in combination with Jounce's PD-1 inhibitor, JTX-4014 -
- Preclinical data highlight Jounce's approach to identif y potential predictive and pharmacodynamic biomarkers to identify patients who may benefit from JTX-8064 -
CAMBRIDGE, Mass., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predic...
Jounce Therapeutics, Inc. (JNCE) CEO Rich Murray on Q3 2020 Results - Earnings Call Transcript
-On track to begin enrollment in the Phase 1 trial for JTX-8064 by year-end 2020-
The company announced disappointing news from a phase 2 study.
CAMBRIDGE, Mass., Oct. 30, 2020 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predic...
These biotechs have a long road ahead, but they just might deliver massive growth.
Jounce Therapeutics: An Undervalued Biotech Flush With Big Pharma Cash
CAMBRIDGE, Mass., Sept. 02, 2020 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and pre...
Gilead (GILD) signs a deal with Jounce Therapeutics to exclusively license the latter's monoclonal antibody, JTX-1811.
Jounce Therapeutics Inc. (NASDAQ: JNCE) made a massive gain on Tuesday after the company announced a licensing agreement with Gilead Sciences Inc.
Shares of Gilead Sciences Inc. GILD, +2.28% were down 0.1% in premarket trading on Tuesday after the drugmaker announced an agreement to exclusively license Jounce Therapeutics Inc.
– Gilead Will Have Exclusive Rights to Develop and Commercialize Anti-CCR8 Antibody –
Jounce Therapeutics' (JNCE) CEO Rich Murray on Q2 2020 Results - Earnings Call Transcript
- Completed enrollment of Phase 2 EMERGE trial for the interim analysis of efficacy and biomarker data in early 2021 -
CAMBRIDGE, Mass., July 31, 2020 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and pred...
- Preclinical data supports the development of JTX-1811, targeting CCR8, as a novel immunotherapy for the selective depletion of immunosuppressive tumor-infiltrating T-regulatory cells -
CAMBRIDGE, Mass., June 10, 2020 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and pred...
These four cancer therapeutics stocks are poised to experience long-term growth. An investment in any of these today could bring huge rewards.
CAMBRIDGE, Mass., June 04, 2020 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and pred...
Jounce Therapeutics, Inc. (JNCE) CEO Rich Murray on Q1 2020 Results - Earnings Call Transcript
Jounce Therapeutics, Inc. (JNCE) CEO Rich Murray on Q4 2019 Results - Earnings Call Transcript
Investors will look forward to pipeline updates when clinical-stage immunotherapy company, Jounce (JNCE), reports Q4 results.
Jounce Therapeutics: An Attractive Immunotherapy Pick For 2020
Jounce Should Be On Your Radar With Differentiated Approach To Activating Immune System
CAMBRIDGE, Mass., Jan. 23, 2020 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and pred...
Is (JNCE) Outperforming Other Medical Stocks This Year?
Slowing trade conflicts and rate cuts by the Federal Reserve boost the domestic economy. The trend is expected to continue in the next year.
Investors need to pay close attention to Jounce Therapeutics (JNCE) stock based on the movements in the options market lately.
A section of the U.S. business community - the small business segment - seems optimistic about the future despite trade-related hiccups.
As of late, it has definitely been a great time to be an investor Jounce Therapeutics, Inc. (JNCE).
About JNCE
Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid tumors. It is also developing JTX-4014, an anti-PD-1 antibody for combination therapy; JTX-8064, an antibody that binds to leukocyte immunoglobulin like receptor B2, which is a cell surface receptor expr... [Read more...]
| Industry Biotechnology | IPO Date Jan 27, 2017 |
| CEO Richard Murray | Employees 128 |
| Stock Exchange NASDAQ | Ticker Symbol JNCE |
Analyst Forecasts
According to 7 analysts, the average rating for JNCE stock is "Buy." The 12-month stock price forecast is 16.00, which is an increase of 86.70% from the latest price.